



Tetrahedron Letters 44 (2003) 1091-1094

TETRAHEDRON LETTERS

Specific oxidation of C-14 oxygenated 4(20),11-taxadienes by microbial transformation

Jungui Dai,^a Shujun Zhang,^b Jun-ichi Sakai,^a Jiao Bai,^b Yoshiki Oku^b and Masayoshi Ando^{a,*}

^aDepartment of Chemistry and Chemical Engineering, Niigata University, Ikarashi 2-8050, Niigata 950-2181, Japan ^bGraduate School of Science and Technology, Niigata University, Ikarashi 2-8050, Niigata 950-2181, Japan

Received 3 October 2002; revised 14 November 2002; accepted 22 November 2002

Abstract—Three C-14 oxygenated taxanes, 2α , 5α , 10β , 14β -tetraacetoxytaxa-4(20),11-diene (1), 2α , 5α , 10β -triacetoxy-14\beta-(2-methylbutyryloxy)taxa-4(20),11-diene (2), and yunanaxane (3), major products of callus cultures of *Taxus* spp., were regio- and stereoselectively hydroxylated at the 7 β position by a fungus, *Absidia coerulea* IFO 4011. Intriguingly, when 1 was co-administered with β -cyclodextrin and incubated with the fungus cell cultures, three other compounds 5α , 9α , 10β , 13α -tetraacetoxytaxa-4(20),11-dien-14\beta-ol (7), 5α , 9α , 10β , 13α -tetraacetoxytaxa-4(20),11-dien-14\beta-ol (7), 5α , 9α , 10β , 13α -tetraacetoxytaxa-4(20),11-dien-15-ol (8) and 5α , 9α , 10β , 13α -tetraacetoxy-11($15 \rightarrow 1$) abeotaxa-4(20), 11-dien-15-ol (9) were obtained. © 2003 Elsevier Science Ltd. All rights reserved.

Taxuyunnanine C [$2\alpha,5\alpha,10\beta,14\beta$ -tetraacetoxytaxa-4(20), 11-diene, **1**], and its analogues, $2\alpha,5\alpha,10\beta$ -triacetoxy-14 β -(2-methylbutyryloxy)taxa-4(20),11-diene (**2**), yunnanxane [$2\alpha,5\alpha,10\beta$ -triacetoxy-14 β -(3-hydroxy-2methylbutyryloxy)taxa-4(20),11-diene, **3**], are the three major C-14 oxygenated taxanes produced by the cell cultures of *Taxus* spp. in high yields (ca. 5–6% of the dry weight).^{1–3} Their high content in the cultures and their taxane-skeleton endow them with valuable potential for the semi-synthesis of paclitaxel (Taxol[®]), one of the most effective anticancer agents, and other structurally related bioactive agents, such as anti-MDR (multi-drug resistance) cancer agents or anti-MDR cancer reversal agents (Scheme 1).^{4–6} Unfortunately, taxanes 1–3, have fewer functional groups bearing on the skeleton in comparison with paclitaxel and other bioactive taxoids in Scheme 1. The regio- and stereoselective introduction of oxygen functional groups at their C-1, C-7, C-9 and C-13 positions seems very difficult through traditional chemical methods. In this context, bioconversion by using microorganisms or plant cell suspension cultures is a potential alternative, and some interesting progress has been achieved.^{7–9} Furthermore, the enzymatic systems of micro-organisms or plant cell cultures may be useful tools to mimic some steps of taxoid biosynthesis and can provide some useful help



Scheme 1.

0040-4039/03/\$ - see front matter @ 2003 Elsevier Science Ltd. All rights reserved. PII: S0040-4039(02)02714-4

Keywords: taxane; oxidation; microbial transformation; *Absidia coerulea* IFO 4011. * Corresponding author. Tel./fax: +81-25-262-7326; e-mail: mando@eng.niigata-u.ac.jp

for the study of taxoid biosynthesis, especially for extensive oxidation of the taxane skeleton. This short communication describes the specific oxidation and rearrangement of these taxanes by the fungus, Absidia coerulea IFO 4011.

First, to 2-day-old cell cultures of a fungus, A. coerulea IFO 4011 (obtained from Institute for Fermentation, Osaka, Japan), 1 was added, and after another week of incubation, 7β hydroxyl product 4 was obtained in 5% yield (Scheme 2). The structure of 4 was determined on the basis of the ¹H NMR, ¹H-¹H COSY, ¹³C NMR, DEPT, HMQC, HMBC, NOE, HREIMS and IR spectra.¹⁰ The HREIMS spectrum of 4 showed an elemental composition of $C_{28}H_{40}O_9$ (found [M]⁺ m/z 520.2666, calcd 520.2672), suggesting that a hydroxyl group may be introduced. The presence of an OH group in 4 was supported by the IR absorption at 3614 cm⁻¹. ¹H and 13 C NMR of 4 also showed the existence of a new oxymethine proton signal at δ 3.90 (1H, dd, J=5.1, 11.7 Hz) and the connected carbon signal at δ 68.92 (d). HMBC correlation of this carbon with H-19, H-9, H-6 and H-5 strongly suggested that the hydroxyl group was introduced at the C-7 position. The stereochemistry of 7-OH was determined to be β -configuration by the NOE difference spectrum; the integration values of H-3, H-6a, H-10 and H-18 were enhanced in 17, 5, 17 and 9%, respectively, when H-7 was irradiated. Therefore, the structure of 4 was determined as 2α , 5α , 10β , 14β -tetraacetoxytaxa-4(20), 11-dien-7 β -ol.

To confirm the specific hydroxylation ability of the fungus and to gain insight into the influence of the different substrates on the biotransformation process, two other related compounds, 2 and 3, were also used as exogenous substrates and incubated with the cell cultures. As expected, 7β hydroxyl products (5, 6) were obtained under the same incubation conditions in 10 and 15% yields (Scheme 2), respectively. Their structures were also determined by spectral methods.^{11,12} It is interesting that the longer the alkyl chain of the acyloxyl groups at C-14 became, the higher the yield of 7-hydroxylated products became.

In an attempt to enhance the yield of 4, β -cyclodextrin, which has been used commonly and successfully in the biotransformation to increase yield,¹³ was co-administered to the cell cultures of the fungus with 1. The yield of the desired product 4 was ca. 5% and was not increased as expected; however, very intriguingly, three other products were produced in addition to 4. Their structures were determined as 5a,9a,10B,13a-tetraacetoxytaxa-4(20),11-dien-14β-ol (7),^{14,15} 5α,9α,10β,13αtetraacetoxytaxa-4(20),11-dien-1 β -ol (8)¹⁶ and 5 α ,9 α , 10β , 13α -tetraacetoxy- $11(15 \rightarrow 1)$ abeotaxa-4(20), 11-dien-15-ol (9)¹⁷(Scheme 3). Compounds 7 and 8 were produced in about 5% yields individually, and 9 in a trace vield.

Product 7 is a known compound which was isolated from the bark of T. mairei.¹⁵ There are substantial differences between the structures of the substrate 1 and product 7, including disappearance of the 2α acetoxyl group, appearance of 9α and 13α acetoxyl groups, and 14 β deactylation. Therefore, product 7 was produced from 1 through several steps (plausibly acetoxyl group intramolecular migration, or acetoxyl group reduction or acetoxylation, etc.).

The molecular formula of 8 was established to be $C_{28}H_{40}O_9$ by combined analyses of the HREIMS, ¹H and ¹³C NMR spectral data. The ¹H NMR spectrum of 8 was similar to that of 7 except the signals of H-1, H-13 and H-14. In the ¹H NMR spectra of 8, the methine proton of H-1 in 7 (δ 1.78, dd, J=2.5, 4.7 Hz) disappeared, and new signals of a methylene proton of H-14 [δ 2.53 (1H, dd, J=10.0, 15.0 Hz), δ 1.61 (1H, m)] appeared. The ¹³C NMR indicated that one hydroxyl group existed at the C-1 position of 8 [δ 76.09 (s)], the location of which was supported by DEPT, HMQC and HMBC experiments. So, the structure of 8 was identified as $5\alpha,9\alpha,10\beta,13\alpha$ -tetraacetoxytaxa-



1

4(20),11-dien-1 β -ol, plausibly produced from 7 via hydroxyl group transfer from C-14 to C-1.

HREIMS showed that **9** had the same molecular formula $C_{28}H_{40}O_9$ as that of **8**. The ¹H, ¹³C NMR, DEPT, HMQC and HMBC spectra of **9** showed unusual chemical shifts for C-1 (δ 62.95, s), and C-15 (δ 75.55, s) compared with those of **8**. The C-11 and C-12 carbon signals showed cross-peaks with H-14 resonances in HMBC, indicating that both C-11 and C-12 were three bonds apart from H-14. These NMR data indicated that **9** should be $11(15 \rightarrow 1)$ abeotaxane.¹⁸ The $11(15 \rightarrow 1)$ abeotaxane **9** was probably produced under the conditions of the biotransformation by the migration of the 11-15 bond to the C-1 position, because $11(15 \rightarrow 1)$ abeotaxanes are observed in *Taxus* plants as natural products.¹⁹

The results suggested that the substrate goes, in the presence of β -cyclodextrin, into the organelles of the cells where there are many different enzymes catalyzing the unusual transformations. We observed a considerable difference in the reaction modes of these biotransformations in the presence and in the absence of β -cyclodextrin. Obviously, the difference in the reaction mode means that each step of taxoid biotransformation takes place in different compartments in the cells. This biotransformation by a fungus gave hypothetical biosynthetic intermediates of paclitaxel and its analogues 4, 7 and 8 from C-14 oxygenated taxoids, in fair yield. Since the availability of taxanes bearing a functionalized group both at C-13 and C-14 such as 7 is very limited in yew trees, this kind of taxane may be the intermediates between C-14 functionalized taxanes and C-13 functionalized taxanes, even the intermediates of paclitaxel biosynthesis. The fact that the functional group at C-2 in 1 was removed after incubation with the fungus cell cultures suggested that the same reaction may take place in the Taxus plant.

In conclusion, here we have reported a useful 7 β hydroxylation and 9 α acetoxylation of C-14 oxygenated taxanes by employing fungus *A. coerulea* IFO 4011 cell cultures. In the latter case the reaction is accompanied by 2 α de-acetoxylation and oxygen functional group transfer to the C-1 and (or) C-13 positions. To our best knowledge, these are the first examples of hydroxylation or acetoxylation of the C-7 or C-13 methylene of taxane derivatives by biocatalytic reactions. These biotransformations would provide not only valuable intermediates for the synthesis of paclitaxel or other bioactive taxoids, but also some helpful hints for the taxoid biosynthetic pathway in the *Taxus* plant.

Acknowledgements

We thank the Japan Society for the Promotion of Science (JSPS) postdoctoral fellowship to J. Dai (ID No. P-01274) and Grant-in-Aid for JSPS Fellows relating to JSPS Postdoctoral Fellowship for Foreign Researchers (No. 1300127). We thank Mr. Sato of the Instrumental Analysis Center for Chemistry, Tohoku University, for the HRMS measurements. J. Dai also thanks the National Natural Science Foundation of China (project No. 30100230) for financial support.

References

- Cheng, K.; Chen, W.; Zhu, W.; Fang, Q. PCT Int. Appl. WO9406, 740 (Cl. C07C35/37), 31 March 1994, JP Appl. 92/249, 047, 18 September 1992.
- Wu, Y.; Zhu, W.; Lu, J.; Hu, Q.; Li, X. Chin. Pharm. J. 1998, 33, 15–18.
- Menhard, B.; Eisenreich, W.; Hylands, P. J.; Bacher, A.; Zenk, M. *Phytochemistry* 1998, 49, 113–125.
- 4. Suffness, M. Ann. Rep. Med. Chem. 1993, 28, 305-315.
- Rowinsky, E. K.; Cazenave, L. A.; Donehower, R. C. J. Natl. Cancer Inst. 1990, 82, 1247–1253.
- Ojima, I.; Bounaud, P. Y.; Bernacki, R. J. Chemtech June. 1998, 31–35.
- Hu, S.; Tian, X.; Zhu, W.; Fang, Q. Tetrahedron 1996, 52, 8739–8746.
- Dai, J.; Guo, H.; Lu, D.; Zhu, W.; Zhang, D.; Zheng, J.; Guo, D. *Tetrahedron Lett.* 2001, 42, 4677–4679.
- Dai, J.; Ye, M.; Guo, H.; Zhu, W.; Zhang, D.; Hu, Q.; Zheng, J.; Guo, D. *Tetrahedron* 2002, *58*, 5659–5668.
- 10. 2α , 5α , 10β , 14β -Tetraacetoxytaxa-4(20), 11-dien-7\beta-ol (4): white powder (mp 79–82°C); $[\alpha]_{D}^{20}$ +47.8° (c 0.140, CHCl₃); IR v_{max} (CHCl₃): 3614, 2972, 2880, 1732, 1646, 1436, 1374, 1240, 1102, 1020 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 1.92 (1H, d, J=2.1 Hz, H-1), 5.40 (1H, dd, J=2.2, 6.6 Hz, H-2), 2.76 (1H, d, J=6.1 Hz, H-3), 5.33 (1H, t, J=2.4 Hz, H-5), 2.12 (1H, m, H-6a), 1.69 (1H, m, H-6β), 3.90 (1H, dd, J=5.1, 11.7 Hz, H-7), 2.23 (1H, dd, $J = 5.1, 15.1 \text{ Hz}, \text{H-}9\alpha), 2.12 (1\text{H}, \text{m}, \text{H-}9\beta), 5.97 (1\text{H}, \text{dd},$ J=5.1, 12.0 Hz, H-10), 2.79 (1H, dd, J=9.3, 19.3 Hz, H-13 β), 2.42 (1H, dd, J = 4.4, 19.0 Hz, H-13 α), 4.95 (1H, dd, J=4.9, 9.3 Hz, H-14), 1.69 (3H, s, H-16), 1.14 (3H, s, H-17), 2.03 (3H, brs, H-18), 0.75 (3H, s, H-19), 5.29 (1H, s, H-20a), 4.93 (1H, s, H-20b), 2.17, 2.07, 2.05, 2.01 [3H each, s, OAc (CH₃)]; ¹³C NMR (CDCl₃, 125 MHz) δ 58.79 (C-1), 70.41 (C-2), 40.55 (C-3), 140.86 (C-4), 77.61 (C-5), 36.87 (C-6), 68.92 (C-7), 44.37 (C-8), 36.94 (C-9), 69.58 (C-10), 135.76 (C-11), 134.92 (C-12), 39.46 (C-13), 70.08 (C-14), 37.34 (C-15), 25.37 (C-16), 31.79 (C-17), 21.70 (C-18), 16.53 (C-19), 118.06 (C-20), 21.46×2, 21.41, 21.14 [OAc (CH₃)], 170.64, 169.99, 169.96, 169.54 [OAc (CO)]; HREIMS m/z calcd for C₂₈H₄₀O₉ 520.2672, found 520.2666.
- 11. 2α,5α,10β-Triacetoxy-14β-(2-methylbutyryloxy)taxa-4(20), 11-dien-7β-ol (**5**): white powder (mp 78–80°C); $[\alpha]_{20}^{20}$ +28.5° (*c* 0.220, CHCl₃); IR ν_{max} (CHCl₃): 3615, 2976, 2940, 2884, 1732, 1646, 1462, 1374, 1250, 1020 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 1.91 (1H, d, *J*=2.0 Hz, H-1), 5.40 (1H, dd, *J*=2.2, 6.6 Hz, H-2), 2.78 (1H, d, *J*=6.6 Hz, H-3), 5.34 (1H, t, *J*=3.4 Hz, H-5), 2.11 (1H, m, H-6α), 1.66 (1H, m, H-6β), 3.90 (1H, dd, *J*=5.1, 12.2 Hz, H-7), 2.22 (1H, dd, *J*=5.3, 15.3 Hz, H-9α), 2.13 (1H, m, H-9β), 5.97 (1H, dd, *J*=5.4, 12.0 Hz, H-10), 2.83 (1H, dd, *J*=9.3, 19.3 Hz, H-13β), 2.37 (1H, dd, *J*=5.4, 19.3 Hz, H-13α), 4.95 (1H, dd, *J*=4.9, 9.0 Hz, H-14), 1.69 (3H, s, H-16), 1.15 (3H, s, H-17), 2.04 (3H, brs, H-18),

0.75 (3H, s, H-19), 5.29 (1H, s, H-20a), 4.89 (1H, s, H-20b), 2.33 (1H, tq, J=7.1, 7.0 Hz, H-2'), 1.62 (1H, ddq, J=7.0, 7.0, 7.3 Hz, H-3'a), 1.46 (1H, ddq, J=7.0, 7.0, 7.3 Hz, H-3'b), 0.89 (3H, t, J=7.3 Hz, H-4'), 1.12 (3H, d, J=7.1 Hz, H-5'), 2.18 [3H, s, 2-OAc (CH₃)], 2.03 [3H, s, 5-OAc (CH₃)], 2.07 [3H, s, 10-OAc (CH₃)]; ¹³C NMR (CDCl₃, 125 MHz) δ 59.10 (C-1), 70.07 (C-2), 40.56 (C-3), 140.85 (C-4), 77.51 (C-5), 36.88 (C-6), 68.89 (C-7), 44.33 (C-8), 36.94 (C-9), 69.60 (C-10), 135.71 (C-11), 135.10 (C-12), 39.65 (C-13), 69.97 (C-14), 37.28 (C-15), 25.35 (C-16), 31.73 (C-17), 21.45 (C-18), 16.57 (C-19), 117.92 (C-20), 175.66 (C-1'), 41.06 (C-2'), 26.74 (C-3'), 11.61 (C-4'), 16.57 (C-5'), 21.77 [2-OAc (CH₃)], 21.12 [5-OAc (CH₃)], 21.34 [10-OAc (CH₃)], 169.59 [2-OAc (CO)], 169.87 [5-OAc (CO)], 170.66 [10-OAc (CO)]; HRMS [+ESI, in MeOH/H₂O (1:1), 3% AcOH, NaCl] m/z calcd for $[C_{31}H_{46}O_9+Na]^+$ 585.30397, found 585.30729; HRMS [-ESI, in MeOH/H₂O (1:1)], calcd for $[C_{31}H_{46}O_9 - H]^+$ 561.31419, found 561.31083.

- 12. 2α,5α,10β-Triacetoxy-14β-(3-hydroxy-2-methylbutyryloxy)taxa-4(20), 11-dien-7 β -ol (6): white powder (mp 89– 91°C); $[\alpha]_D^{20}$ +31.4° (*c* 0.60, CHCl₃); IR v_{max} (CHCl₃): 3624, 2992, 2936, 1732, 1646, 1606, 1458, 1374, 1318, 1102, 1020 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 1.92 (1H, d, J=2.0 Hz, H-1), 5.40 (1H, dd, J=2.2, 6.6 Hz,H-2), 2.76 (1H, d, J=6.3 Hz, H-3), 5.34 (1H, t, J=3.2Hz, H-5), 2.09 (1H, m, H-6a), 1.69 (1H, m, H-6β), 3.90 (1H, dd, J=5.1, 11.7 Hz, H-7), 2.23 (1H, dd, J=5.1, 15.1)Hz, H-9 α), 2.14 (1H, m, H-9 β), 5.97 (1H, dd, J = 5.1, 12.0Hz, H-10), 2.83 (1H, dd, J=9.0, 19.0 Hz, H-13 β), 2.38 $(1H, dd, J=4.7, 19.0 Hz, H-13\alpha), 4.99 (1H, dd, J=4.7,$ 9.0 Hz, H-14), 1.69 (3H, s, H-16), 1.14 (3H, s, H-17), 2.04 (3H, brs, H-18), 0.75 (3H, s, H-19), 5.30 (1H, s, H-20a), 4.90 (1H, s, H-20b), 2.40 (1H, dq, J=7.0, 7.3 Hz, H-2'), 3.87 (1H, dq, J=7.0, 6.3 Hz, H-3'), 1.21 (3H, d, J=6.4 Hz, H-4'), 1.16 (3H, d, J=7.3 Hz, H-5'), 2.18, 2.07, 2.03 [3H each, s, OAc (CH₃)]; ¹³C NMR (CDCl₃, 125 MHz) δ 58.97 (C-1), 69.99 (C-2), 40.58 (C-3), 140.82 (C-4), 77.57 (C-5), 36.94 (C-6), 69.51 (C-7), 44.35 (C-8), 36.89 (C-9), 69.53 (C-10), 135.83 (C-11), 134.81 (C-12), 39.48 (C-13), 70.56 (C-14), 37.30 (C-15), 25.34 (C-16), 31.72 (C-17), 21.38 (C-18), 16.56 (C-19), 118.02 (C-20), 174.78 (C-1'), 47.00 (C-2'), 68.92 (C-3'), 20.87 (C-4'), 14.02 (C-5'), 21.76, 21.44, 21.13 [OAc (CH₃)], 170.60, 169.84, 169.55 [OAc (CO)]; HREIMS m/z calcd for $C_{31}H_{46}O_{10}$ 578.3091, found 578.3087.
- Woerdenbag, H.; Pras, N.; Frijlink, H.; Lerk, C.; Malingre, T. M. *Phytochemistry* **1990**, *29*, 1551–1554.
- 14. 5α,9α,10β,13α-Tetraacetoxytaxa-4(20),11-dien-14β-ol (7): white powder (mp 205–208°C; lit.¹⁵ mp 208–209°C); $\{[\alpha]_D^{20}$ +80.7° (*c* 1.733, CHCl₃); lit.¹⁵ $[\alpha]_D^{24}$ +76.4° (*c* 0.480, CHCl₃)}; IR v_{max} (CHCl₃): 3620, 2968, 1732, 1648, 1440, 1374, 1134, 1020 cm⁻¹; HREIMS *m/z* calcd for C₂₈H₄₀O₉ 520.2672, found 520.2664; the NMR data of 7 are in good agreement with those reported in lit. 15.

- 15. Shi, Q.; Oritani, T.; Kiyota, H. Nat. Prod. Lett. 1998, 12, 85–90.
- 16. 5α , 9α , 10β , 13α -Tetraacetoxytaxa-4(20), 11-dien-1\beta-ol (8): white powder (mp 80–82°C); $[\alpha]_{D}^{20}$ +88.9° (c 1.007, CHCl₃); IRv_{max} (CHCl₃): 3620, 3024, 2968, 1734, 1648, 1440, 1374, 1136, 1018 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) & 1.89 (1H, dd, J=8.5, 14.2 Hz, H-2a), 1.75 (1H, dd, J=5.9, 14.2 Hz, H-2b), 2.94 (1H, d, J=5.9 Hz, H-3), 5.37 (1H, t, J=2.7 Hz, H-5), 1.85 (1H, m, H-6a), 1.73 (1H, m, H-6b), 1.80 (2H, m, H-7), 5.87 (1H, d, J=10.8 Hz, H-9), 6.07 (1H, d, J = 10.8 Hz, H-10), 6.03 (1H, t, J = 8.0 Hz, H-13), 2.53 (1H, dd, J = 10.0, 15.0 Hz, H-14a), 1.61 (1H, m, H-14b), 1.62 (3H, s, H-16), 1.19 (3H, s, H-17), 2.10 (3H, d, J=1.0 Hz, H-18), 0.76 (3H, s, H-19), 5.24 (1H, d, J=1.2 Hz, H-20a), 4.91 (1H, d, J=1.2 Hz, H-20b), 2.08 [3H, s, 5-OAc (CH₃)], 2.02 [3H, s, 9-OAc (CH₃)], 2.05 [3H, s, 10-OAc (CH₃)], 2.16 [3H, s, 13-OAc (CH₃)]; ¹³C NMR (CDCl₃, 125 MHz) δ 76.09 (C-1), 38.10 (C-2), 41.49 (C-3), 147.80 (C-4), 76.22 (C-5), 27.23 (C-6, C-7), 43.18 (C-8), 76.76 (C-9), 72.03 (C-10), 134.49 (C-11), 138.93 (C-12), 70.96 (C-13), 41.43 (C-14), 43.58 (C-15), 27.12 (C-16), 21.95 (C-17), 14.84 (C-18), 17.67 (C-19), 114.27 (C-20), 20.99 [5-OAc (CH₃)], 21.36 [9-OAc (CH₃)], 21.78 [10-OAc (CH₃)], 20.72 [13-OAc (CH₃)], 169.82 [5-OAc (CO)], 170.34 [9-OAc (CO)], 169.82 [10-OAc (CO)], 170.20 [13-OAc (CO)]; HREIMS m/z calcd for C₂₈H₄₀O₉ 520.2672, found 520.2671.
- 17. $5\alpha,9\alpha,10\beta,13\alpha$ -Tetraacetoxy-11(15 \rightarrow 1)abeotaxa-4(20),11dien-15-ol (9): white powder (mp 200–202°C); $[\alpha]_{D}^{20}$ –20° (c 0.08, CHCl₃); IR v_{max} (CHCl₃): 3620, 3020, 2964, 1732, 1644, 1370, 1120, 1018 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 2.17 (1H, dd, J=8.3, 14.4 Hz, H-2a), 1.38 (1H, d, J=14.2 Hz, H-2b), 2.70 (1H, d, J=8.5 Hz, H-3), 5.30 (1H, t, J=2.7 Hz, H-5), 1.88 (1H, m, H-6a), 1.78 (1H, m, H-6b), 1.72 (2H, m, H-7), 5.78 (1H, d, *J*=10.2 Hz, H-9), 6.15 (1H, d, J=10.2 Hz, H-10), 5.52 (1H, t, J=7.6 Hz, H-13), 2.48 (1H, dd, J=7.3, 13.9 Hz, H-14a), 1.21 (1H, m, H-14b), 1.31 (3H, s, H-16), 1.14 (3H, s, H-17), 1.83 (3H, d, J=1.0 Hz, H-18), 0.77 (3H, s, H-19), 5.17 (1H, s, H-20a), 4.76 (1H, s, H-20b), 2.03, 2.01, 2.00, 1.99 [3H each, s, OAc (CH₃)]; ¹³C NMR (CDCl₃, 125 MHz) δ 62.95 (C-1), 29.26 (C-2), 40.29 (C-3), 147.04 (C-4), 75.07 (C-5), 27.37 (C-6), 27.79 (C-7), 41.91 (C-8), 77.86 (C-9), 69.57 (C-10), 137.74 (C-11), 145.15 (C-12), 79.43 (C-13), 44.33 (C-14), 75.55 (C-15), 24.73 (C-16), 27.09 (C-17), 11.52 (C-18), 16.85 (C-19), 112.28 (C-20), 21.16, 21.00, 20.88, 20.77 [OAc (CH₃)], 170.54, 170.10, 169.66, 168.66 [OAc(CO)]; HREIMS m/z calcd for C₂₈H₄₀O₉ 520.2672, found 520.2684.
- Preparation by biotransformation: Hu, S.; Sun, D.; Tian, X.; Fang, Q. *Tetrahedron Lett.* 1997, 38, 2721–2724.
- (a) Kiyota, H.; Shi, Q.; Oritani, T.; Li, L. *Biosci. Biotechnol. Biochem.* 2001, *65*, 35–40 and references cited therein;
 (b) Baloglu, E.; Kingston, G. I. *J. Nat. Prod.* 1999, *62*, 1448–1472.